Loading company…
Seoul-based maker of iPSC-derived cell products for research, drug discovery and regenerative medicine.
NEXEL Co., Ltd. was founded in 2012 in Seoul, South Korea, and develops human induced pluripotent stem cell (iPSC)-derived cell products. Its products are used in research, drug discovery, regenerative medicine and disease modeling, and are sold mainly in North America and Europe to pharmaceutical companies, academic institutions and biotech firms. The company has completed 11 deals and, as of September 6, 2023, had raised a total of KRW 1 billion in venture funding against a current valuation of KRW 126,348.327 mn. Its CEOs are listed as Anders Vikkelsø and Choong-seong Han.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in